Fig. 3From: Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseasesDistribution of FDA orphan drug designations with at least one approval within therapeutic area, 1983–2019Back to article page